Arcus Biosciences, Inc. has terminated its global Phase 3 STAR-221 study evaluating domvanalimab, an investigational anti-TIGIT antibody, in combination with zimberelimab and chemotherapy for advanced upper gastrointestinal cancers. The discontinuation, announced in partnership with Gilead Sciences, Inc., followed a pre-specified interim overall survival analysis that found no benefit compared to the nivolumab-based control arm. Arcus Biosciences is now redirecting its research and development efforts toward its HIF-2α inhibitor casdatifan and a growing portfolio of oral small molecules targeting inflammatory and autoimmune diseases.
Why the STAR-221 failure is a pivotal inflection point for Arcus Biosciences
The collapse of STAR-221 is not an isolated clinical failure. It represents a broader reckoning for anti-TIGIT immunotherapy combinations that have not delivered consistent survival benefits in large randomized trials. Industry analysts following checkpoint inhibitor strategies have pointed to an increasingly skeptical regulatory and investor environment for TIGIT-based therapies, especially after the mixed or negative data emerging from other programs such as Roche’s tiragolumab.
In the case of Arcus Biosciences, domvanalimab had been positioned as a differentiated, Fc-silent TIGIT-blocking antibody with theoretical safety and efficacy advantages. However, the STAR-221 trial, which compared domvanalimab plus zimberelimab and chemotherapy to nivolumab-based regimens, failed to demonstrate an improvement in overall survival. The combination’s safety profile was comparable to standard treatment, but without survival benefit, the therapeutic rationale for advancing this particular combination in upper gastrointestinal cancers appears to have evaporated.
This outcome may impact the perceived value of Arcus Biosciences’ broader TIGIT and anti-PD-1 pipeline, especially as it had formed a key part of the strategic collaboration with Gilead Sciences. The decision to shut down not just STAR-221 but also the Phase 2 EDGE-Gastric study reinforces a clear pivot away from gastrointestinal oncology as a priority. Clinicians and regulatory observers will be watching whether other ongoing domvanalimab studies, including those in non-small cell lung cancer, undergo further scrutiny or de-prioritization.
What casdatifan’s clinical momentum reveals about Arcus Biosciences’ new strategic center of gravity
In stark contrast to the fading domvanalimab program, casdatifan has emerged as the company’s central oncology asset. A small molecule HIF-2α inhibitor, casdatifan is being developed for clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer. The ARC-20 Phase 1/1b study has already reported encouraging data in more than 120 late-line ccRCC patients, showing improved overall response rate and progression-free survival relative to belzutifan, the only marketed drug targeting this pathway.
Arcus Biosciences appears to be betting on casdatifan’s potential to become a best-in-class HIF-2α inhibitor. The compound, designed to deeply and durably block HIF-2α signaling, is being evaluated across both immunotherapy-experienced and treatment-naïve metastatic ccRCC populations. The company’s development strategy includes studying casdatifan both as monotherapy and in combination with cabozantinib, a standard-of-care tyrosine kinase inhibitor. Additional data from multiple ARC-20 cohorts, along with potential initiation of a Phase 3 registrational trial by late 2026, suggests an accelerated timeline toward approval.
Industry observers note that HIF-2α is a validated but competitive target. While Merck & Co.’s belzutifan secured first-mover advantage, its modest efficacy and safety limitations leave room for improvement. Arcus Biosciences’ argument that casdatifan delivers more durable responses, especially in earlier treatment lines, will need to be validated by larger, longer-duration studies. If the upcoming PEAK-1 and eVOLVE-RCC02 studies reinforce early findings, casdatifan could quickly become the company’s most valuable commercial asset.
Why the inflammation and immunology pipeline matters more now than ever
Arcus Biosciences is not only pivoting within oncology but expanding decisively into the inflammation and immunology space. The company’s pipeline now includes five oral small molecule programs targeting high-value immunological pathways such as MRGPRX2, TNF, CCR6, CD89 and CD40L. This represents a shift from injectable biologics toward small molecule therapeutics with the potential for superior convenience, dosing flexibility and manufacturing scalability.
The company plans to advance its MRGPRX2 inhibitor into clinical trials in 2026, targeting diseases such as atopic dermatitis and chronic spontaneous urticaria. This would be followed by a TNF inhibitor program in late 2026 or early 2027 aimed at rheumatoid arthritis, psoriasis and inflammatory bowel disease, including ulcerative colitis.
This pipeline diversification is being closely watched by analysts, as the autoimmune drug market remains one of the most commercially attractive in biopharma. Oral agents have historically faced challenges in terms of selectivity, toxicity and durability. However, Arcus Biosciences is pitching its candidates as potentially best-in-class, building on molecular designs optimized for target specificity and tolerability. The competitive bar remains high, with established players in the autoimmune space and next-generation JAK inhibitors already in the market. Regulatory clarity will be essential, especially for novel targets like MRGPRX2 that lack extensive clinical precedent.
How Arcus Biosciences’ financial strength underpins its ability to execute this pivot
At a time when many mid-cap biopharmaceutical firms are struggling to raise capital or are forced into strategic mergers, Arcus Biosciences finds itself in an enviable financial position. With approximately one billion dollars in cash and investments on hand, the company expects to be able to fund operations through at least the second half of 2028. This gives it a rare opportunity to reallocate R&D resources without facing immediate pressure from investors or capital markets.
This financial cushion allows Arcus Biosciences to prioritize high-probability programs, expand its clinical footprint in renal oncology and I&I diseases, and make go-no-go decisions with discipline rather than desperation. Investors will now focus on how the company stages its next round of clinical catalysts, including the upcoming ARC-20 data readouts in early and mid-2026, and potential entry of its autoimmune programs into the clinic.
That said, capital alone cannot guarantee success. The failure of STAR-221 is a reminder that even well-capitalized programs can falter when clinical biology does not align with therapeutic expectations. Arcus Biosciences must now prove that its remaining pipeline is differentiated, executable and aligned with regulatory expectations in an increasingly cautious drug approval environment.
What could go wrong next—and where scrutiny is likely to intensify
Despite the apparent clarity of Arcus Biosciences’ new R&D direction, risks remain substantial. While casdatifan’s early data are encouraging, they are not yet registrational, and combination trials always carry additive toxicity risks. If casdatifan fails to replicate its early efficacy in larger cohorts or shows safety concerns when paired with cabozantinib, its best-in-class aspirations could fade.
The I&I pipeline, though full of promise, is preclinical. Moving from early research to successful clinical translation requires a different set of capabilities—both scientific and operational. Analysts also caution that novel targets such as MRGPRX2 may run into hurdles related to biomarker selection, indication narrowing, and regulatory unfamiliarity.
The partnership with Gilead Sciences may also be tested. The failure of STAR-221 undermines a key joint development asset, and it is unclear how much appetite Gilead Sciences has for continued co-investment in programs without clear short-term returns. While the collaboration remains intact for now, investor sentiment will likely track whether Gilead Sciences renews or de-emphasizes its commitments to Arcus Biosciences’ remaining oncology pipeline.
What this portfolio reset reveals about Arcus Biosciences’ long-term thesis
The shift away from TIGIT-based combinations toward small molecule innovation marks a generational reset for Arcus Biosciences. It reflects the reality that immune checkpoint inhibition, once seen as a nearly universal solution for cancer, is now facing saturation and biological complexity in many tumor types. By focusing on new mechanisms in oncology and chronic inflammatory diseases, the company is attempting to build a more resilient and diversified growth engine.
If casdatifan delivers in pivotal trials, and if the first autoimmune candidates enter the clinic with solid preclinical data and regulatory traction, Arcus Biosciences could be well positioned by 2027 to operate across two high-value therapeutic verticals. However, the pressure is on to demonstrate execution, differentiate meaningfully, and show investors that this pivot is not just reactive, but strategic.
What Arcus Biosciences’ STAR-221 failure reveals about TIGIT fatigue in immunotherapy added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →